Chemokine Receptor Antagonists: Role in Oncology

Purpose of Review To evaluate the clinical potential of chemokine receptor antagonists for the treatment of patients with cancer. Recent findings Chemokine receptors and their ligands can have a significant impact on the infiltration of cells into the tumor microenvironment. The receptors are increasingly being investigated as targets for the treatment of cancers. Recent studies are demonstrating the promise of chemokine receptor antagonists in this setting. There are many chemokine receptors, and each can have different functions depending on the cellular context. Targeting chemokine receptors is a promising strategy in both pre-clinical research and clinical trials. Inhibiting chemokine receptors that either recruit suppressive cells or improve cancer mobility and viability while sparing those necessary for proper immune trafficking may prove to dramatically improve treatment responses. Further research in this area is warranted and has the potential to dramatically improve patient outcomes.

Automated summary

Chemokine receptor antagonists show promise in cancer treatment by influencing cell infiltration into the tumor microenvironment. Targeting different chemokine receptors is a promising strategy for improving treatment responses in cancer patients. Additional research in this area has the potential to dramatically enhance patient outcomes.